Regulated information

Sales 3rd quarter 2023: 136M€

The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.

Sustainable development, an integral part of Vetoquinol

Vetoquinol's corporate vision underlines its ambition for its entire ecosystem. This vision creates a dynamic for sustainable development by stating that by 2033 the company will be "the most agile animal health laboratory where employees, experts, partners, and customers work together to create customized solutions dedicated to animal health for a better planet".

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

Mastaplex and Vetoquinol announce distribution agreement

Mastaplex Ltd (New Zealand, unlisted) and Vetoquinol (VETO: France Euronext) are pleased to announce an extension of their exclusive distribution agreement for Mastatest..

Growth driven by innovation

Ever since the company was founded in 1933, innovation has been a major component of Vetoquinol's development strategy.

3rd generation appointed chairman of the board of directors of VETOQUINOL SA

At the Combined General Meeting it was also announced that Mr. Etienne Frechin will resign as Chairman of the Board of Vetoquinol, effective 1st July 2023. Mr. Etienne Frechin will remain a Director of the company, hence continuing to share his broad experience. On 25 May 2023, the Board of Directors appointed Mr. Matthieu Frechin, Chief Executive Officer of the Group, as Chairman of the Board of Directors of Vetoquinol effective 1st July 2023.

Essential products

Essential products for the most common needs

Worlds Top 10

The animal health company is firmly established in the world's Top 10. 

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).